BioCryst Pharma downgraded by Evercore ISI with a new price target
$BCRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Evercore ISI downgraded BioCryst Pharma from Outperform to In-line and set a new price target of $8.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/13/2026 | $12.00 | Neutral | Analyst |
| 2/18/2026 | $17.00 | Outperform | Evercore ISI |
| 10/15/2025 | $30.00 | Buy | TD Cowen |
| 10/1/2025 | $8.00 | Outperform → In-line | Evercore ISI |
| 4/29/2025 | $20.00 | Overweight | Cantor Fitzgerald |
| 2/25/2025 | $15.00 | Outperform | Wedbush |
| 11/20/2023 | $10.00 | Overweight | JP Morgan |
| 9/18/2023 | $9.00 → $10.00 | Sector Perform → Outperform | RBC Capital Mkts |
4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
8-K - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)
8-K - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)
144 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)
RESEARCH TRIANGLE PARK, N.C., July 22, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2026 financial results on Wednesday, August 5, 2026. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema ("HAE") and other rare diseases,
RESEARCH TRIANGLE PARK, N.C., July 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) ("BioCryst" or the "Company") today announced the appointment of David W. Jenkins, MA, PhD, to the newly created position of Chief Scientific Officer, effective immediately, reporting to Dr. Sandeep Menon, Chief Research and Development Officer. In this role, Dr. Jenkins will build and lead an efficient research team focused on leveraging external innovation, capabilities and partnerships to accelerate the delivery of transformative rare disease therapies to patients. He will be based in the Company’s Boston office. Dr. Jenkins has spent over 20 years working in the biopharmaceutic
RESEARCH TRIANGLE PARK, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees stock options to purchase an aggregate of 33,950 shares, and restricted stock units (RSUs) covering an aggregate of 91,750 shares, of BioCryst common stock. The options and RSUs were granted as of July 1, 2026, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $9.65 per share, which is equal to the closing price of B
Analyst resumed coverage of BioCryst Pharma with a rating of Neutral and set a new price target of $12.00
Evercore ISI resumed coverage of BioCryst Pharma with a rating of Outperform and set a new price target of $17.00
TD Cowen resumed coverage of BioCryst Pharma with a rating of Buy and set a new price target of $30.00
RESEARCH TRIANGLE PARK, N.C., July 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) ("BioCryst" or the "Company") today announced the appointment of David W. Jenkins, MA, PhD, to the newly created position of Chief Scientific Officer, effective immediately, reporting to Dr. Sandeep Menon, Chief Research and Development Officer. In this role, Dr. Jenkins will build and lead an efficient research team focused on leveraging external innovation, capabilities and partnerships to accelerate the delivery of transformative rare disease therapies to patients. He will be based in the Company’s Boston office. Dr. Jenkins has spent over 20 years working in the biopharmaceutic
— Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval — RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the appointment of Sandeep M. Menon, MD, PhD, as Chief Research and Development Officer. Building on the commercial success of ORLADEYO® and the recent acquisition of Astria Therapeutics and the navenibart program, BioCryst is entering a new phase of execution in its strategy to build value through development and commercialization of rare disease therapies. Dr. Menon joins BioCryst from Alnylam Pharmaceuticals, where he served as Chief Devel
RESEARCH TRIANGLE PARK, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new findings from patient-focused research highlighting the burden of current treatments for HAE on pediatric patients under the age of 12 and their caregivers and perspectives on the importance of HAE treatments. The findings will be presented in posters at the 2025 US HAEA National Summit in Baltimore, which is taking place July 10-13, 2025. "For more than a decade, we have been honored to join the HAE patient community at the US HAEA National Summit. It is an opportunity for us to hear directly from them on their hopes and dreams
RESEARCH TRIANGLE PARK, N.C., July 22, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2026 financial results on Wednesday, August 5, 2026. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema ("HAE") and other rare diseases,
— Q1 2026 ORLADEYO® net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on comparable basis excluding European revenue) — — Announced licensing agreement for European commercial rights to navenibart for $70M upfront and milestone payments up to $275M — RESEARCH TRIANGLE PARK, N.C., May 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today reported financial results for the quarter ended March 31, 2026, and provided a business update. "We began 2026 with continued strong execution across our business, led by sustained growth of ORLADEYO and solid progress across our pipeline," said Charlie Gayer, President and Chief Executive Officer of BioCryst. "ORLADEYO con
RESEARCH TRIANGLE PARK, N.C. , April 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2026 financial results on Wednesday, May 6, 2026. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst is a global biotechnolo
SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)
SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)
SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)